Physician profile
John N May
NPI 1104054667
$3,471.05
in general payments reported to CMS, 2019-2025
33 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $485 · 2021: $725 · 2022: $485 · 2023: $209 · 2024: $515 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.02 | 2019-2025 | |
| Amgen INC. | $467.25 | 2019-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $365.81 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $271.87 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $180.34 | 2019-2022 | |
| Medtronic, INC. | $151.45 | 2025 | Intellis Adaptivestim, Symplicity G3 |
| Lilly USA, LLC | $141.44 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Amarin Pharma, INC. | $138.33 | 2020-2022 | |
| Pfizer INC. | $136.38 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.84 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $100.25 | 2019-2021 | |
| Eisai INC. | $74.31 | 2020-2021 | |
| Allergan, INC. | $68.91 | 2019-2020 | |
| Dexcom, INC. | $59.41 | 2024 | Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $49.99 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.28 | 2021-2023 | Xifaxan, Trulance |
| Cranial Technologies, INC | $41.44 | 2024-2025 | Doc Band |
| Glaxosmithkline, LLC. | $41.11 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $39.76 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.91 | 2022 | |
| Nevro Corp. | $33.66 | 2022 | |
| Abbott Laboratories | $32.78 | 2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $29.77 | 2024 | Gemtesa |
| Daiichi Sankyo INC. | $24.64 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.36 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.33 | 2022 | |
| Inspire Medical Systems, INC. | $18.77 | 2023 | Inspire |
| Sunovion Pharmaceuticals INC. | $17.59 | 2021 | |
| Exact Sciences Corporation | $14.53 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $11.41 | 2021 | |
| Esperion Therapeutics, INC. | $11.10 | 2021 | |
| Genentech USA, INC. | $11.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.